1.
Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131labeled monoclonal antibody BW575/9 to external beam radiotherapy in human
neuroblastoma xenografts. Strahlenther Onkol 1993;169:595-600.
2.
Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. A mutation in the puff region
of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant
of coxsackievirus B3. J Virol. 1996;70:7811-8.
3.
Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU. NFkappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus
virulence: a mechanism of resistance in p50 knockout mice. J Virol. 1998;72:5654-60.
4.
Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU. Low-level expression of a mutant
coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of
enteroviral persistence in cardiac myocytes. Circulation. 1998;98:450-457.
5.
Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, Kandolf R,
Knowlton KU. Transgenic expression of replication-restricted enteroviral genomes in heart
muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin
Invest. 1998;102:1444-53.
6.
Wessely R, Klingel K, Knowlton KU, Kandolf R. Cardioselective Infection With
Coxsackievirus B3 Requires Intact Type I Interferon Signaling : Implications for Mortality and
Early Viral Replication. Circulation. 2001;103:756-761.
7.
Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandl R, Murr A,
Klein CA, Baeuerle PA. Transcriptome analysis reveals a role of interferon-gamma in human
neointima formation. Mol Cell. 2001;7:1059-69.
8.
Wessely R, Hengst L, Jaschke B, Wegener F, Richter T, Lupetti R, Paschalidis M,
Schomig A, Brandl R, Neumann FJ. A central role of interferon regulatory factor-1 for the
limitation of neointimal hyperplasia. Hum Mol Gen. 2003;12:177-187.
9.
Wessely R, Fateh-Moghadam S, Bocksch W, Jager G, Hetzer R, Gawaz M.
Cytomegalovirus Infection Predicts Progression of Heart Transplant Vasculopathy.
Transplantation. 2003;76:1470-1474.
10.
Wessely R. Coxsackieviral replication and pathogenicity: lessons from gene modified
animal models. Med Microbiol Immunol. 2004, 193(2-3):71-74
11.
Wessely R, Paschalidis M, Wagenpfeil S, Wegener F, Neumann FJ, Theiss W. A
comprehensive approach to visual and functional assessment of experimental vascular
lesions in vivo. Am J Physiol Heart Circ Physiol. 2004; 286(6):H2461-2467.
12.
Jaschke B, Milz S, Wegener F., Schömig A, Kastrati A, Wessely R. Local cyclindependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell
proliferation and migration: implications for the applicability on drug eluting stents to
prevent neointima formation following vascular injury. FASEB J. 2004;18(11):1285-1287
13.
Wessely R, Fateh-Moghadam S, Jaeger G, Bocksch W, Hetzer R, Gawaz M.
Cytomegalovirus and progressing heart transplant vasculopathy: enough evidence that
needs to be translated in appropriate screening and treatment regimens. Transplantation.
2004;78:632-633
14.
Wessely R, Vorpahl M, Schömig A, Klingel K. Late constrictive involvement of the
pericardium in a case of previous myocarditis. Cardiovasc Pathol. 2004;13:327-329.
15.
Wessely R, Seidl S, Schömig A. Cardiac involvement in Emery-Dreifuss muscular
dystrophy. Clin Genet. 2005;67:220-223.
16.
Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B,
Schratzenstaller T, Renke-Gluszko M, Stöver M, Wintermantel E, Kastrati A, Schömig A.
Inhibition of neointima formation by a novel drug-eluting stent system that allows for doseadjustable, multiple and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005; 25:748753.
17.
Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R. Targeting 2A protease
by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in
highly susceptible mice. Circulation. 2005;111:1583-1592
18.
Wessely R. Interference by interferons: Janus faces in vascular proliferative diseases.
Cardiovascular Res 2005;66:433-443
19.
Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, RenkeGluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schomig A. Prevention of restenosis
by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent
coating. Eur Heart J. 2005;26(15):1475-81
20.
Ott I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, Zohlnhofer D,
Wessely R, Rudelius M, Schomig A, Carmeliet P. Vascular remodeling in mice lacking the
cytoplasmic domain of tissue factor. Circ Res. 2005;97(3):293-8.
21.
Fröhlich G, Porner M, Wessely R. Aortic coarctation visualized by 16-row detector
multislice computed tomography. Circulation. 2005;112(6):e81.
22.
Wessely R, Pache J, Schomig A. Recurrence of in-stent restenosis in cardiac allograft
vasculopathy following implantation of a sirolimus-eluting stent. Transpl Int.
2005;18(9):1113-5.
23.
Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R,
Dirschinger J, Schomig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353(7):663-70.
24.
Wessely R, Kastrati A, Schomig A. Late restenosis in patients receiving a polymercoated sirolimus-eluting stent. Ann Intern Med. 2005;143(5):392-4.
25.
Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A,
Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial
cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res.
2005;68(3):483-92.
26.
Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy:
back to the future? Circulation. 2005;112(18):2759-61.
27.
Wessely R. Paclitaxel-eluting stents with erodable polymer appear safe. Commentary.
Evid Based Cardiovasc Med. 2005;9(4):297-300.
28.
Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J,
Schomig A; Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2
Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based
rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of
late lumen loss. Circulation. 2006;113(2):273-9.
29.
Wessely R, Schomig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drugeluting stents: similar but different. J Am Coll Cardiol. 2006;47(4):708-14.
30.
Wessely R, Bradaric C, Seybold S. Ruptured vulnerable coronary plaque and Tc-99m
sestamibi-based assessment of infarct size. Clin Nucl Med. 2006;31(6):331-2.
31.
Stöver M, Renke-Gluszko M, Schratzenstaller T, Will J, Klink N, Behnisch B, Kastrati A,
Wessely R, Hausleiter J, A. S, Wintermantel E. Microstructuring of stainless steel implants by
electrochemical etching. J Mater Sci. 2006;41:5569-5575.
32.
Wessely R, Augustin N. Porner M, Schomig A, Lange R. Giant coronary aneurysm
obstructing the right heart. Lancet. 2006 Jul 29;368(9533):386.
33.
Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schomig A, Kastrati A. Vessel size and
outcome after coronary drug-eluting stent placement: results from a large cohort of patients
treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48(7):1304-9.
34.
Xiong D, Yajima T, Lim BK, Stenbit A, Dublin A, Dalton ND, Summers-Torres D,
Molkentin JD, Duplain H, Wessely R, Chen J, Knowlton KU. Inducible cardiac-restricted
expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy.
Circulation. 2007;115:94-102.
35.
Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A, Blaich B,
Iijima R, Pache J, Kastrati A, Schömig A. Does addition of estradiol improve the efficacy of a
rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol.
2007;49;1265-71
36.
Merl S, Wessely R. Anti-coxsackieviral efficacy of RNA interference is highly
dependent on genomic target selection and emergence of escape mutants.
Oligonucleotides. 2007;17:44-53
37.
Wessely R, Blaich B, BelAiba RS, Merl S, Görlach A, Kastrati A, Schömig A.
Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel
and sirolimus: implications for local drug delivery. Thromb Haemost. 2007; 97:1003-12
38.
Wessely R, Botnar RM, Vorpahl M, Schwaiger M, Schömig A, Ibrahim T. Subacute
thrombotic occlusion and spontaneous recanalization of the right coronary artery following
PCI for STEMI visualized by coronary angiography and cardiac MRI. Circulation 2007;116:e7880
39.
Schulz C, Kreß W, Schömig A, Wessely R. Endocardial cushion defect in a patient with
Crouzon syndrome carrying a mutation in the fibroblast growth factor receptor (FGFR)-2
gene. Clin Genet. 2007;72:305-7
40.
Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A. Randomized trial of
rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and
design. Eur Heart J. 2007;28:2720-5
41.
Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R,
Schömig A, Kastrati A; for the Intracoronary Stenting and Angiographic Restenosis
Investigators – Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating
Strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different
coating strategies for the reduction of coronary restenosis. Eur Heart J. 2008;29(16):197582.
42.
John MC, Wessely R, Kastrati A, Schömig A, Joner M, Uchihashi M, Crimins J, Listhrop
RA, Kolodgie F, Gold HK, Virmani R, Finn A. Differential healing response in polymer vs. nonpolymer based sirolimus eluting stents. JACC Cardiovasc Interv, 2008;1:535-544
43.
Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R, Vogeser M,
Hausleiter J, Joner M, Schömig A, Wessely R. The pre-clinical assessment of rapamycineluting, durable polymer-free stent coating concepts. Biomaterials, 2009;30(4):632-7
44.
Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A,
Kastrati A for the COntrast media and NephroToxicity following coronary Revascularization
by AngioplaSTy (CONTRAST) trial investigators. Choice of contrast medium in patients with
impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc
Interv, 2009;5:430-7
45.
Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol, 2010;4:194-203
46.
Wessely R., Reddan D. Contrast media, cardiovascular interventions and kidney
injury: does contrast osmolarity matter? Eur Nephrol, 2010;4:62-67
47.
Wessely R. Atherosclerosis and cell cycle – put the brakes on! Critical role for cyclindependent kinase inhibitors. J Am Coll Cardiol, 2010;55:2269-71
48.
Merl S., Wessely R. RNA interference to treat enteroviral disease: current status and
clinical perspectives. Curr Mol Ther, 2010;10:550-64
49.
Wessely R. Initial experience with an institutional bridging protocol for patients with
recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy
due to urgent surgery. Am J Ther, 2011:280-282
50.
Poll LW, Sadra B, Rühlow S, Wessely R. Thrombosis of a large saphenous vein graft
aneurysm leading to acute myocardial infarction 21 years after coronary artery bypass
grafting: role of cardiac multi-slice computed tomography. Interact Cardiovasc Thorax Surg
2011:284-286
51.
Wessely R, Andres V. Limus is not limus– a proposal to adjust terminology in the
context of drug-eluting stents. J Cardiovasc Pharmacol 2012;59:485-86
52.
Tolg R, Zeymer U, Birkemeyer R, Wessely R, Eggebrecht H, Bocksch W, Schneider S,
Richardt G, Hamm C. Cardiogoniometry as a diagnostic tool in patients with acute coronary
syndromes. Results of the CGM@ACS trial. Clin Res Cardiol 2012;101:727-36
53.
Birkemeyer R, Toelg R, Zeymer U, Wessely R, Jäckle S, Hairedini B, Lübke M, Aßfalg M,
Jung W. Comparison of Cardiogoniometry and electrocardiography with perfusion cardiac
magnetic resonance imaging and late gadolinium enhancement. Europace 2012, in press
54.
Wessely R. Cardiogoniometry – an evolving, simple-to-use technology for detection
of underlying cardiovascular disease in patients presenting with acute chest pain. Hosp
Healtcare Eur, in press.
55.
Wessely R, Hernández F, Laville, M, Fonseca T. Renal and cardiac safety of isoosmolar versus hyper-osmolar contrast media associated with invasive arterial
cardiovascular procedures in high-risk patients. A systematic review and meta-analysis of
randomized controlled trials. Submitted 2013
56.
Vorpahl, M, Schönhofer-Merl S, Michaelis C, Flotho A, Melchior F, Wessely R.
Ran GTPase-Activating Protein mediated Differentiation and Attenuation of Migration and
Proliferation in Vascular Smooth Muscle Cells. Submitted 2013.
57.
Vorpahl M, Wessely R. Bioabsorbable stents – status quo. Submitted 2013.
58.
Wessely R, Paunovic D. Long-term follow-up of coronary venous bypass graft lesions
treated with a new generation DES with bioabsorbable polymer: insights from the NOBORI 2
registry. Submitted 2013